PRIMO 2017


Thursday, January 31, 2019

The state of cancer care in 2019 Charles Balch
Hematologic Malignancies
NHL/CLL: Where are we making progress? Julie Vose
Myelodysplastic Syndromes (MDS): The right treatments for the right patients Naval Daver
Acute Myelogenous Leukemia (AML): Making sense of the options Naval Daver
Diffuse Large B-Cell Lymphoma: Is R-CHOP alone enough? Julie Vose
Multiple Myeloma: Updates and options Sagar Lonial
Multiple Myeloma: What do we do in early relapse? Rafael Fonseca

Friday, February 1, 2019

Melanoma/Sarcoma/GU/GI
Melanoma: A new paradigm in adjuvant therapy Sanjiv Agarwala
Soft Tissue Sarcoma Shane Morita
RCC Update: Is immunotherapy front-line again? Ravi Madan
What is the best first-line option for hormone resistant prostate cancer? Donald Trump
Bladder Cancer: Where does immunotherapy fit in? Ravi Madan
Updates in GI Cancers Alan Venook
Lung/HNC
NSCLC: First-line treatment – Immunotherapy, combination chemoimmunotherapy, or targeted therapy? Julie Brahmer
SCLC: Finally, something new! Paul Bunn
Immunotherapy in HNSCC: Are we ready for a paradigm shift? Hyunseok Kang

Saturday, February 2, 2019

Breast Cancer
Updates in the treatment of hormone receptor positive breast cancer in early and late stage disease Hope S. Rugo
Precision medicine meets breast oncology: Molecular testing to direct treatment decisions William Gradishar
Optimal therapy for early stage HER2+ breast cancer: A new menu of options Mark Pegram
Immunotherapy for breast cancer: When, in which patients and what’s next? Hope S. Rugo
New treatment options for metastatic HER2+ breast cancer William Gradishar
Key meeting takeaways Hope S. Rugo